Dexmeditomidine is estimated to have a 2-selectivity that is 7–8 times greater than that of clonidine, making it a more effective agonist for the 2-adrenergic receptor than clonidine. It operates as an anxiolytic in the locus cerulean by stimulating presynaptic adrenoreceptors. Intravenous Dexmeditomidine was effective as a primary sedative in initially intubated and mechanically ventilated patients in an intensive care setting, as well as in non-intubated patients prior to and/or during surgical and other procedures, according to the results of randomized, double-blind, placebo-controlled, multicenter studies.